Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Colorcon
Teva
Harvard Business School
Farmers Insurance
Daiichi Sankyo
Argus Health
Novartis
Baxter
US Department of Justice

Generated: August 20, 2017

DrugPatentWatch Database Preview

FENOGLIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Fenoglide, and when can generic versions of Fenoglide launch?

Fenoglide is a drug marketed by Santarus Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in eleven countries.

The generic ingredient in FENOGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

Summary for Tradename: FENOGLIDE

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list80
Clinical Trials: see list1
Patent Applications: see list6,067
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FENOGLIDE at DailyMed

Pharmacology for Tradename: FENOGLIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Santarus Inc
FENOGLIDE
fenofibrate
TABLET;ORAL022118-001Aug 10, 2007ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Santarus Inc
FENOGLIDE
fenofibrate
TABLET;ORAL022118-002Aug 10, 2007ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Santarus Inc
FENOGLIDE
fenofibrate
TABLET;ORAL022118-001Aug 10, 2007ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Santarus Inc
FENOGLIDE
fenofibrate
TABLET;ORAL022118-002Aug 10, 2007ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Santarus Inc
FENOGLIDE
fenofibrate
TABLET;ORAL022118-001Aug 10, 2007ABRXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FENOGLIDE

Drugname Dosage Strength RLD Submissiondate
fenofibrateTablets40 mg and 120 mgFenoglide3/17/2010

Non-Orange Book Patents for Tradename: FENOGLIDE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,772,273Stabilized atorvastatin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FENOGLIDE

Country Document Number Estimated Expiration
Russian Federation2343905► Subscribe
China1867321► Subscribe
European Patent Office1680091► Subscribe
Canada2582405► Subscribe
Russian Federation2006115596► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Argus Health
Julphar
Express Scripts
Dow
Baxter
Harvard Business School
Accenture
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot